Neuroimaging – Products

Aptamer inks £360K deal with a top pharma to develop Optimer® radiopharmaceuticals targeting cancer.

Roche reveals new data on trontinemab and pTau217 testing, aiming to transform Alzheimer’s treatment and diagnosis.

A new study highlights IsoPSA’s ability to identify low-risk prostate cancer patients who can avoid unnecessary interventions. The test also helps monitor high-risk patients more closely.

Ascelia Pharma AB (publ) (ticker: ACE), announced that liver imaging drug candidate, Orviglance®, significantly improved visualization of focal liver lesions, successfully meeting the primary endpoint in the pivotal Phase 3 study SPARKLE.

Research partnership aims to build strong pharma and academic collaborations in sharing data and clinical samples to develop biomarker-based diagnostics for Alzheimer’s Disease.

Study confirms ALZmetrixTM whole blood test can detect people at high risk of developing full Alzheimer’s Disease.

Oncodesign Services announces the execution of a Preclinical License and Supply Agreement with ImaginAb Inc. for the use of their investigational CD8 ImmunoPET™ (89Zr crefmirlimab berdoxam) technology.

Cleveland Diagnostics, Inc., a commercial-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, has opened a new, state-of-the-art facility.

Personalis, Inc., Cancer Research UK’s Cancer Research Horizons, University College London and the Francis Crick Institute have announced a collaboration to deploy a personalized liquid biopsy-based research assay, for the TRACERx study.

Bruker Corporation has announced the signing of the definitive agreement to purchase 100% of the shares of Neurescence Inc., an innovative provider of ultralight fiber-bundle MultiscopesTM for simultaneous multi-region, optical functional neuroimaging.